{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:45:06Z","timestamp":1787021106809,"version":"build-2736575974"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We present a rare case of TNF-\u03b1 inhibitor induced pigmented purpuric dermatoses (PPD) and explore its mechanisms and management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 44-year-old woman presented with non-pruritic non-tender petechial rash on bilateral lower limbs after being started on Adalimumab, with the rash progressing to worsen on Golimumab, both used for managing her seronegative peripheral arthritis. Laboratory panel revealed a negative vasculitis screen and skin biopsy confirmed the condition. After ceasing the TNF-\u03b1 inhibitors and changing to Secukinumab, an Interleukin-17 inhibitor, the lesions stopped erupting and slowly resolved.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PPD is a benign skin condition and has been associated with various medications and exposure to chemicals in the literature. Different mechanisms have been proposed in the literature however its exact aetiology is unknown. To date, there is no standardized treatment however patients should be reassured that PPD is benign and will often regress by itself once the causative agent has been removed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41927-022-00255-1","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T19:05:13Z","timestamp":1651172713000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["TNF-\u03b1 inhibitor induced pigmented purpuric dermatoses: a case report"],"prefix":"10.1186","volume":"6","author":[{"given":"Divita","family":"Jhaveri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5924-987X","authenticated-orcid":false,"given":"Frances","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,29]]},"reference":[{"key":"255_CR1","unstructured":"Tolaymat L, Hall MR. Pigmented purpuric dermatitis. StatPearls Publishing; 2021 [updated\u00a02021 July 26]. Available from Pigmented Purpuric Dermatitis\u2014StatPearls\u2014NCBI Bookshelf (nih.gov)."},{"issue":"1","key":"255_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4103\/2229-5178.93486","volume":"3","author":"L Sharma","year":"2012","unstructured":"Sharma L, Gupta S. Clinicoepidemiological study of pigmented purpuric dermatoses. Indian Dermatol Online J. 2012;3(1):17\u201320.","journal-title":"Indian Dermatol Online J"},{"issue":"4","key":"255_CR3","doi-asserted-by":"publisher","first-page":"404","DOI":"10.5021\/ad.2015.27.4.404","volume":"27","author":"DH Kim","year":"2015","unstructured":"Kim DH, Seo SH, Ahn HH, Kye YC, Choi JE. Characteristics and clinical manifestations of pigmented purpuric dermatosis. Ann Dermatol. 2015;27(4):404\u201310.","journal-title":"Ann Dermatol"},{"issue":"2 Pt 1","key":"255_CR4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0190-9622(94)70016-8","volume":"30","author":"P von den Driesch","year":"1994","unstructured":"von den Driesch P, Simon M Jr. Cellular adhesion antigen modulation in purpura pigmentosa chronica. J Am Acad Dermatol. 1994;30(2 Pt 1):193\u2013200.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"255_CR5","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/j.1365-4362.1995.tb04419.x","volume":"34","author":"I Ghersetich","year":"1995","unstructured":"Ghersetich I, Lotti T, Bacci S, Comacchi C, Campanile G, Romagnoli P. Cell infiltrate in progressive pigmented purpura (Schamberg\u2019s disease): immunophenotype, adhesion receptors, and intercellular relationships. Int J Dermatol. 1995;34(12):846\u201350.","journal-title":"Int J Dermatol"},{"issue":"2","key":"255_CR6","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1309\/AQMU3JFE2A66LC7E","volume":"128","author":"CM Magro","year":"2007","unstructured":"Magro CM, Schaefer JT, Crowson AN, Li J, Morrison C. Pigmented purpuric dermatosis: classification by phenotypic and molecular profiles. Am J Clin Pathol. 2007;128(2):218\u201329.","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"255_CR7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/j.1600-0560.1991.tb01378.x","volume":"18","author":"BR Smoller","year":"1991","unstructured":"Smoller BR, Kamel OW. Pigmented purpuric eruptions: immunopathologic studies supportive of a common immunophenotype. J Cutan Pathol. 1991;18(6):423\u20137.","journal-title":"J Cutan Pathol"},{"issue":"7","key":"255_CR8","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/j.1365-4632.2004.02213.x","volume":"43","author":"K Sardana","year":"2004","unstructured":"Sardana K, Sarkar R, Sehgal VN. Pigmented purpuric dermatoses: an overview. Int J Dermatol. 2004;43(7):482\u20138.","journal-title":"Int J Dermatol"},{"issue":"4","key":"255_CR9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1525-1470.2001.01932.x","volume":"18","author":"P Tristani-Firouzi","year":"2001","unstructured":"Tristani-Firouzi P, Meadows KP, Vanderhooft S. Pigmented purpuric eruptions of childhood: a series of cases and review of literature. Pediatr Dermatol. 2001;18(4):299\u2013304.","journal-title":"Pediatr Dermatol"},{"key":"255_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4078\/jrd.2014.21.1.9","volume":"21","author":"SH Moon","year":"2014","unstructured":"Moon SH, Ko JY. Dermatological side effects of anti-tumor necrosis factor alpha therapy. J Rheum Dis. 2014;21:9\u201319.","journal-title":"J Rheum Dis"},{"issue":"1","key":"255_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.autrev.2013.06.005","volume":"13","author":"G Fiorino","year":"2014","unstructured":"Fiorino G, Danese S, Pariente B, Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-\u03b1 agents. Autoimmun Rev. 2014;13(1):15\u20139.","journal-title":"Autoimmun Rev"},{"issue":"11","key":"255_CR12","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1084\/jem.20072707","volume":"205","author":"CA Notley","year":"2008","unstructured":"Notley CA, Inglis JJ, Alzabin S, McCann FE, McNamee KE, Williams RO. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med. 2008;205(11):2491\u20137.","journal-title":"J Exp Med"},{"issue":"3","key":"255_CR13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/cei.12626","volume":"181","author":"DN Hull","year":"2015","unstructured":"Hull DN, Williams RO, Pathan E, Alzabin S, Abraham S, Taylor PC. Anti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis. Clin Exp Immunol. 2015;181(3):401\u20136.","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"255_CR14","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1136\/annrheumdis-2011-201024","volume":"71","author":"S Alzabin","year":"2012","unstructured":"Alzabin S, Abraham SM, Taher TE, Palfreeman A, Hull D, McNamee K, et al. Incomplete response of inflammatory arthritis to TNF\u03b1 blockade is associated with the Th17 pathway. Ann Rheum Dis. 2012;71(10):1741\u20138.","journal-title":"Ann Rheum Dis"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-022-00255-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-022-00255-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-022-00255-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T19:07:24Z","timestamp":1651172844000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-022-00255-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,29]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["255"],"URL":"https:\/\/doi.org\/10.1186\/s41927-022-00255-1","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,29]]},"assertion":[{"value":"2 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics exemption has been approved by the Human Research Ethics Committee, Metro South Health, Queensland EX\/2021\/QMS\/76444.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient has provided written consent for publication of clinical materials relevant to the case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}